Jiangsu Simcere Pharmaceutical Co., Ltd.
Clinical trials sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd., explained in plain language.
Pharmaceutical company developing innovative drugs, subsidiary of Simcere.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New Dual-Action antibody enters first human trials for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called SIM0689 in adults with advanced solid tumors that have stopped responding to standard treatments. SIM0689 is a bispecific antibody designed to block two cancer-promoting pathways (PD1 and VEGF). The trial will first find a safe dose,…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New eczema drug shows promise in Mid-Stage trial
Disease control Not yet recruitingThis study tests a new injectable drug called SIM0278 for adults with moderate to severe atopic dermatitis (eczema) that needs systemic treatment. About 184 participants will receive either a low, medium, or high dose of SIM0278 or a placebo. The main goal is to see how much ecze…
Phase: PHASE2 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC